Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-08-21
2010-10-12
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S249000, C514S252190, C514S253090, C514S254020, C514S254050, C514S278000, C514S316000, C514S326000, C514S338000, C544S130000, C544S141000, C544S058200, C544S058500, C544S295000, C544S349000, C544S354000, C544S364000, C544S370000, C544S372000, C546S015000, C546S187000, C546S194000, C546S208000, C546S276700
Reexamination Certificate
active
07812021
ABSTRACT:
The invention relates to a compound of general formulawhereinAr, R1, R2, R3, R4, n, o, p, s, X andare as defined herein or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
REFERENCES:
patent: 5576333 (1996-11-01), Miller
patent: 2006/0020011 (2006-01-01), Wu et al.
patent: 0714891 (1996-06-01), None
patent: 2000136 (1979-01-01), None
patent: WO 98/27086 (1998-06-01), None
Tooney et al., Neurosci. Letters, 2000, vol. 283 pp. 185-188.
Giardina et al., Exp. Opin. Ther. Patents, 2000, vol. 10, pp. 939-960.
Jung et al., Neuroscience, 1996, vol. 74 pp. 403-414.
Leslie et al., Neuropeptides, 1998, vol. 32 pp. 481-488.
Kamali et al., Current Opinion in Investigational Drugs, 2001, vol. 2(7) pp. 950-956.
Dega-Szafran et al., J. Molecular Structure, 2001, vol. 560 p. 261.
Jablonski Philippe
Kawasaki Ken'ichi
Knust Henner
Limberg Anja
Nettekoven Matthias
Bernhardt Emily
Hoffmann-La Roche Inc.
Johnstone George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
Pyrrolidine aryl-ether as NK3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidine aryl-ether as NK3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine aryl-ether as NK3 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4209786